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Estrogen receptor b activation impairs mitochondrial oxidative
metabolism and affects malignant mesothelioma cell growth
in vitro and in vivo
AG Manente1, D Valenti2, G Pinton1, PV Jithesh3, A Daga4, L Rossi5, SG Gray6, KJ O’Byrne6, DA Fennell7, RA Vacca2,
S Nilsson8,9, L Mutti10 and L Moro1
Estrogen receptor (ER)-b has been shown to possess a tumor suppressive effect, and is a potential target for cancer therapy. Using
gene-expression meta-analysis of human malignant pleural mesothelioma, we identified an ESR2 (ERb coding gene) signature.
High ESR2 expression was strongly associated with low succinate dehydrogenase B (SDHB) (which encodes a mitochondrial
respiratory chain complex II subunit) expression. We demonstrate that SDHB loss induced ESR2 expression, and that activated ERb,
by over-expression or by selective agonist stimulation, negatively affected oxidative phosphorylation compromising mitochondrial
complex II and IV activity. This resulted in reduced mitochondrial ATP production, increased glycolysis dependence and impaired
cell proliferation. The observed in vitro effects were phenocopied in vivo using a selective ERb agonist in a mesothelioma mouse
model. On the whole, our data highlight an unforeseen interaction between ERb-mediated tumor suppression and energy
metabolism that may be exploited to improve on the therapy for clinical management of malignant mesothelioma.
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INTRODUCTION
Estrogen receptor (ER)-b is the second ER subtype identified in
several human tissues traditionally known to be ER negative.1,2
It has been recently reviewed that ERb is expressed and exerts anti-
proliferative effects in different human tumor models, for example,
breast, colon, prostate, T-cell lymphoma, medulloblastoma, glioma
and pleural mesothelioma.3–5 Therefore, drugs with selectivity for
ERb could theoretically suppress tumor growth without having the
serious side effects linked to drugs traditionally associated with
ERa. To this end, several ERb-selective agonists have been
designed6–13 that are either in preclinical or early clinical trials.14,15
Our group recently demonstrated that ERb, but not ERa, is
expressed in malignant pleural mesothelioma (MMe) cells, where
it acts as a tumor suppressor by modulation of the transcription of
several genes coding for proteins involved in cell growth control,
cell cycle progression and apoptosis, and that its expression is
associated with longer patient survival.16,17
MMe is a rare but increasingly prevalent, highly aggressive
cancer with poor prognosis.18 The etiology is essentially a function
of previous exposure to asbestos fibers, which are considered to
be an early-stage carcinogen for MMe that, causing chronic
inflammation, may lead to reactive mesothelial hyperplasia and
subsequent cancer development.19,20
MMe is a highly treatment-resistant and insidious cancer.
The current treatment is multimodal, and a patient may receive
a combination of chemotherapy, surgery or radiotherapy
treatments.21,22 Patients not eligible for curative surgery receive
antimetabolite (Alimta) in combination with cisplatin, which is the
standard first-line therapy.23 This chemotherapeutic combination
has, however, moderate efficacy and poor safety profile.24 There
is no defined second-line option. Recent advances in under-
standing the disease’s complex biology have led to moderate
improvements in the effectiveness of the standard therapies,
resulting in an increase in median survival times.25,26 However,
despite reported improvements in the clinical management of
MMe, the unmet need for improved treatment is high. We studied
MMe cells as a model to achieve a better understanding of the
underlying mechanisms that mediate ERb anticancer activity and
its therapeutic applications focusing on the effects on energy
metabolism.
Reprogramming of energy metabolism is one of the hallmarks
of cancer. In normal conditions, cells rely on mitochondrial
oxidative phosphorylation (OXPHOS) to provide energy for cellular
activities. The general enhancement of the glycolytic machinery in
various cancer cell lines is well described.27 The aerobic use of
glucose as an energy source through glycolysis in turn leads to a
lesser dependence on OXPHOS, which is called the Warburg
effect.28 Although some studies demonstrate a reduction of
OXPHOS capacity in cancer cells, other investigations reveal
contradictory modifications with the upregulation of OXPHOS
1Department Pharmaceutical Sciences, University of Piemonte Orientale ‘A. Avogadro’, Novara, Italy; 2CNR-IBBE, Bari, Italy; 3Liverpool Cancer Research UK Centre, University of
Liverpool, Liverpool, UK; 4IRCCS San Martino-IST, Genova, Italy; 5Department of Human Morphology and Applied Biology, University of Pisa, Pisa, Italy; 6Institute of Molecular
Medicine, St James’s Hospital, Dublin, Ireland; 7MRC Toxicology Unit, University of Leicester and Leicester University Hospitals, Leicester, UK; 8Karo Bio AB, Huddinge, Sweden;
9Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden and 10Department of Medicine, S. Andrea Hospital, Vercelli, Italy. Correspondence: Professor
L Moro, Dipartimento di Scienze del Farmaco, Universita` degli Studi del Piemonte Orientale ‘A. Avogadro’, via Bovio 6, Novara 28100, Italy.
E-mail: moro@pharm.unipmn.it
Received 5 April 2013; revised 27 June 2013; accepted 16 July 2013
Citation: Oncogenesis (2013) 2, e72; doi:10.1038/oncsis.2013.32
& 2013 Macmillan Publishers Limited All rights reserved 2157-9024/13
www.nature.com/oncsis
components and a larger dependency of cancer cells on oxidative
energy substrates for anabolism and energy production. This
apparent conflictual picture is explained by differences in tumor
size, hypoxia, and the sequence and repertoir of oncogenes
activated.29–32
In this study, we aimed to determine the link between
ERb activation and alterations of aerobic energy metabolism.
For the first time, we disclose a novel mechanism by which
activated ERb impairs the activity of mitochondrial respi-
ratory chain (MRC) complexes, forcing cells to depend on
glycolysis.
Our findings provide an innovative rationale to treat human
cancers by selective activation of ERb, and highlight the
potential use of ERb-selective agonists alone or in combination
with glycolysis inhibitors for efficacious malignant mesothelioma
therapy with significantly improved side-effect profile.
RESULTS
Expression of succinate dehydrogenase B negatively correlates with
ESR2 expression in human MMe cells
In silico analysis of microarray data on biopsies from MMe patients
was performed to generate an ESR2 expression meta-signature.
Two publicly available microarray gene-expression data sets from
93 MMe tumors, GSE 2549 (n¼ 40) and GSE 29354 (n¼ 53) were
analyzed. Raw data was pre-processed and normalized using
Robust Multichip Average method, and the median expression
level for the probe set 210780 was used to stratify the samples
into ‘High ESR2’ or ‘Low ESR2’. Following analysis of variance
to adjust for batch variance and find contrast between the two
classes, there were 159 probe sets upregulated group and
13 probe sets downregulated in the ‘High ESR2’ group (FDR
adjusted Po0.05, fold-change 4|2|). Among downregulated
genes, we identified succinate dehydrogenase B (SDHB),
coding for the B subunit of MRC complex II. The observed
negative correlation between ESR2 and SDHB expression was
validated by ERb and SDHB western blot analysis of tissue
samples (n¼ 20) from MMe patients with different histological
subtypes. Densitometric analysis and a representative western
blot are shown in Figures 1a and b. To establish whether it is
ESR2 that control SDHB expression, we evaluated both SDHB
mRNA and protein levels in the MMe-derived REN cells trans-
fected with vectors to over-express or silence ESR2. We observed
that ESR2 modulation did not influence SDHB gene trans-
cription (Figure 1c), even though there was a negative correlation
between ERb and SDHB-expressed proteins (Figures 1d and e).
In order to validate in vivo data, we investigated whether
SDHB silencing in REN cells could affect ESR2 gene expression.
Quantitative real-time PCR (Figure 1f) and western blot analysis
(Figures 1g and h) documented a significant increase in both
ESR2 transcription and in ERb-expressed protein in SDHB-silenced
cells.
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Figure 1. ERb expression inversely correlates with SDHB expression. (a) Bar graph showing the densitometric ratio of SDHB to ERb evaluated
by western blot analysis in tissue samples from MMe patients with different histological subtypes (total number: 20). ‘High’ or ‘low’ expressors
were defined using the same criteria used for mRNA meta-analysis. (b) A representative western blot analysis of ERb and SDHB expression in
tissue samples. (c) Relative SDHB mRNA levels measured by real-time PCR in Mock, ERb over-expressing (ERb) and ERb-silenced (shERb) REN
cells. (d) A representative western blot analysis of MRC subunits expression in Mock, ERb over-expressing and ERb-silenced REN cells. (e) SDHB
quantitative densitometry of the western blot analysis. (f ) ERb mRNA expression evaluated by real-time PCR in non-specific control siRNA (c
siRNA) or SDHB-silenced (siRNA SDHB) REN cells. (g) Western blot analysis of ERb and SDHB expression in non-specific c siRNA and SDHB-
silenced REN cells. (h) ERb quantitative densitometry of the western blot analysis. Each graph is representative of three independent
experiments. Each bar represents mean±s.d. *Po0.05.
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SDHB silencing causes alterations in the activity of MRC complexes
without affecting cell proliferation
To study the impact of SDHB subunit loss on mitochondrial
function in vitro, SDHB was silenced by transient small interfering
RNA (siRNAs) transfection of REN cells. A dramatic reduction in
complex II, a noticeable decrease in complex III and a slight
increase in complex IV activities were observed (Figure 2a). This
confirms the fundamental role of the SDHB subunit for the activity
of complex II and, in part, also for complex III, whereas the
increased activity of complex IV can be regarded as a secondary
compensatory effect to the inhibition of complex II and III.33,34
It has been shown that respiratory chain dysfunctions could lead
to an increase in compensative mitochondrial biogenesis.35–37
In our studies, we could demonstrate that SDHB silencing led
to a significant increase in the number of mitochondria, as
assessed by electron microscopy analysis, and in mitochondrial
mass (Figures 2b and c). As demonstrated by real-time PCR
(Figure 2d), the observed increases corresponded to a rise in the
mitochondrial DNA (mtDNA) content, confirming mitochondrial
biogenesis. On the basis of our previous data, documenting the
role of ERb as tumor suppressor in MMe,16,17 we expected a
reduction in the growth rate of SDHB-silenced cells beause of the
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Figure 2. SDHB silencing leads to alteration in the activity of MRC complexes, mitochondrial biogenesis but not cell proliferation.
(a) Spectrophotometric evaluation of MRC complexes enzymatic activities in non-specific control siRNA (c siRNA) and SDHB- (siRNA SDHB)
silenced REN cells. (b) Electron microscopy analysis performed to observe mitochondrial number and morphology in non-specific control
siRNA and SDHB-silenced REN cells. Arrowheads indicate some of the mitochondria, scale bars correspond to 2.5 mm in top left, 3.33 mm in top
right, 0.5 mm in bottom left and 0.66 mm in bottom right. N, nucleus. (c) Mitochondrial mass per cell determined in c siRNA and SDHB-silenced
REN cells using the cardiolipin-selective dye, NAO. (d) Changes in mtDNA content relative to the nuclear DNA calculated by real-time PCR of
the D-loop and ACTB genes in c siRNA and SDHB-silenced REN cells. (e) Growth curves of REN cells transfected with empty vector (Mock),
SDHB siRNA, ERb expression vector (ERb) or ERb siRNA at 24 and 48h. Each bar represents mean±s.d. *Po0.05.
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strong increase in ERb expression. However, the cell proliferation
analysis clearly showed that, differently from ERb over-expression
or silencing, the transient knockdown of SDHB did not affect cell
growth compared with control cells (Figure 2e).
SDHB silencing in the presence of ERb activation augments
alterations in the activity of MRC complexes and affects cell
growth
To get an understanding for the lack of effect on cell proliferation
after transient SDHB knockdown, we performed a western blot
analysis of cell fractions to determine the localization of ERb in
SDHB-silenced cells. ERb, when over-expressed by transient
transfection, was predominantly found in the nucleus, while,
when induced by SDHB silencing, it was mainly retained in the
cytosol and translocated to the nucleus only upon activation by its
selective ligand KB9520 (Figure 3a). Activation of ERb by KB9520
and diarylpropionitrile (DPN), two different selective ligands,
resulted in strong impairment of complex II and IV activity both
in control and SDHB-silenced cells (Figure 3b). Real-time PCR
analysis demonstrated that ERb activation by over-expression or
binding of selective ligands resulted in the reduced expression of
COX7AR, which is a nuclear gene coding for an assembly subunit
of complex IV, necessary for its full activity (Figure 3c). Over-
expression of ERb mutated in the DNA-binding domain (DBD)
opposed the repressive effects of wild-type ERb on COX7AR
expression, supporting an important role of ERb DBD in the
transcriptional regulation of COX7AR (Supplementary Figures
1A–C). No variations in COX2, COX4.1 and COX4.2 subunits
expression were observed under these conditions (data not
shown). Furthermore, ERb activation by KB9520 impaired pro-
liferation of SDHB-silenced cells (Supplementary Figure 2A).
Importantly, KB9520 and DPN did not severely impair MRC
complex II and IV activities, COX7AR expression or cell proliferation
of normal ERb-positive mesothelial MET5A cells (Supplementary
Figures 3A–C) and human mesothelial cells (HMC; data not
shown), suggesting that selective agonist activation of ERb is not
cytotoxic to normal cells.
ERb activation compromises the activity of MRC complexes and
tumor growth in vivo
To reinforce the role of ERb as a pivotal factor in ERb-positive
tumor cells bio-energetic homeostasis, the in vitro studies were
repeated in a mesothelioma in vivo model. Six-week-old CD1 nude
male mice were inoculated with 2 106 REN or 1 106 MSTO-
211H MMe cells by intraperitoneal (i.p.) injection (7 animals/
group). Before inoculation, the MMe cells were transduced with a
lentiviral vector carrying the luciferase gene to allow imaging in
live mice. Fifteen days after cell inoculation, tumor incidence in
the peritoneal cavity was 100% in all animal groups. The ERb-
selective agonist KB9520 (10mg/kg body weight/day), dissolved in
the vehicle, was administrated once daily by subcutaneous
injection. Untreated animals were subcutaneously dosed with
empty vehicle. Animals injected with the ERb-negative MSTO-
211H cells showed a dramatic increase of tumor growth that was
not reduced by KB9520 treatment compared with MSTO-211H
vehicle control mice (Figures 4a and b). Animals in these
treatment arms had to be killed after 10 days of treatment due
to their massive tumor growth. In contrast, KB9520 treatment of
mice injected with REN cells, which express endogenous ERb,
resulted in a decrease in tumor dimensions as compared with
vehicle controls within 10 days of treatment (Figures 4a and b). In
2 out of 7 KB9520-treated mice, a reduction in initial tumor mass
was observed after 20 days of treatment, whereas 5 out of 7 mice
KB9520 inhibited the rate of tumor growth as compared with
vehicle control mice. Treatment with KB9520 was not toxic to the
animals as assessed by monitoring changes of mice body weights
during the 20 days drug administration. After 35 days from
inoculation, all animals were killed. In vivo treatment of REN cell
tumors with daily doses of KB9520 resulted in upregulation of ERb
at both mRNA and protein levels (Supplementary Figures 4A and
B). Interestingly, in tumor tissues recovered from REN-injected
mice, 20 days of KB9520 treatment resulted in a strong
impairment in MRC complexes II and IV activities (Figure 4c),
confirming results obtained in REN cells in vitro. Moreover, as
evidenced by real-time PCR experiments reported in Figure 4d,
and as observed in vitro, the expression of COX7AR was reduced in
tumor tissues from KB9520-treated REN-injected mice compared
with vehicle control mice.
Modulation of ERb levels affects mitochondrial functions
To stress the role of ERb in metabolic control, MRC activity was
evaluated in REN cells over-expressing ERb. The results, shown in
Figure 5a, provide evidence that very high expression of ERb
strongly impaired complex II and IV activities, and that ERb
silencing, on the contrary, led to a significant increase in complex
III and IV functionality. To confirm that alterations in MRC
complexes activities had consequences on mitochondrial ATP
production, we performed a spectrophotometric measurement
of the mitochondrial ATP production in ERb-silenced and
over-expressing cells. We observed that ERb over-expression
significantly reduced mitochondrial ATP production at basal levels
and in response to stimuli with complexes I and II substrates
(Figure 5b). In contrast, silencing of ERb led to a marked increase
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Figure 3. ERb activation affects MRC complexes activity in vitro.
(a) ERb western blot analysis of cytosolic and nuclear fractions
derived from REN cells, transfected with empty vector (Mock), ERb
expression vector (ERb) or with SDHB siRNA treated±10 nm KB9520,
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in mitochondrial ATP production both under basal conditions and
after stimuli (Figure 5b). In ERb over-expressing cells, differently
from SDHB-silenced cells, the alterations in mitochondrial activity
were not compensated by an increase in mitochondrial biogen-
esis, mitochondrial mass or mtDNA content (Figures 5c–e).
ERb activation sensitizes cells to glycolysis
As ERb compromises mitochondrial activity, to prove that ERb
over-expressing cells became more glycolysis dependent, we
investigated cell growth in glucose-deprived medium. As shown
in Figure 6a, ERb over-expression compromised cell viability in the
absence of glucose, supporting the glycolysis dependence of
these cells. Moreover, to further explore dependence on glycolysis,
we treated ERb over-expressing, ERb-silenced and parental
REN cells with KB9520 in the presence of the hexokinase
inhibitor 2-Deoxy-D-glucose (2DG) or the PFKFB3 kinase inhibitor
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO).38 In all experi-
mental conditions, glycolysis inhibitors potentiated the effects of
over-expressed or KB9520-activated ERb (Figures 6b and c).
DISCUSSION
Our group has recently demonstrated that the ERb subtype exerts
a key role as a tumor-suppressor gene in MMe.16,17 In this report,
we provide support for an entirely novel mechanism by which
activated ERb interferes with functions of MRC complexes and
mitochondrial ATP production in tumor cells (Figure 7).
By in silico analysis of microarray data from 93 MMe patients, we
generated an ESR2 expression meta-signature. Among down-
regulated genes, as a function of ERb protein levels, we identified
SDHB coding for a subunit of the MRC complex II. SDH, also known
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experiments. Each bar represents mean±s.d. *Po0.05.
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as succinate:quinone oxidoreductase, is a key enzyme in
intermediary metabolism and aerobic energy production, cou-
pling the oxidation of succinate in the Krebs cycle to the reduction
of ubiquinone in the electron transport chain.39 The MRC
complex II is composed of four nuclear-encoded subunits whose
alterations have been related to many different diseases: SDHA
mutations have been associated to Leigh syndrome, mito-
chondrial encephalopathy, and optic atrophy40 and SDHB, SDHC
and SDHD alterations have been correlated to hereditary
pheochromocytoma and paraganglioma.41 Also in MMe, the
SDHB gene locus (1p36.1–p35) has been shown to be
significantly altered in copy number.42 In paraganglioma and
pheochromocytoma, sporadic and familial mutations in the SDHB
gene support a link between mitochondrial dysfunction and
tumorigenesis. In contrast, loss of SDHB in the REN malignant
mesothelioma cell line is associated with antitumorigenic effects.
That knockdown of SDHB in REN cells did not result in anti-
proliferative effects, despite the fact that increased ERb expression
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is best explained by the predominant cytoplasmic localization of
ERb in the absence of ligand activation and the compensatory
increase in mitochondrial biogenesis.
The mechanistic explanation for the negative correlation
between SDHB and ERb expression in MMe patients and in vitro
in the REN MMe cell line is, however, still unknown and needs
further exploration.
Cytochrome c oxidase is the last and the largest of the MRC
complexes, and the assembly of all its 13 subunits is necessary
for its full activity; the 11-subunit form, devoid of subunits COX6A
and COX6B, retains 85–90% of electron transport activity, whereas
the 9-subunit form that lacks two additional subunits (COX3
and COX7AR) has only 40–45% of intact enzyme activity.43 In this
report, we demonstrate that ERb activation, by over-expression
or selective agonist activation, caused a dramatic loss of the
MRC complex IV function. The most likely explanation for this
effect in vitro and in vivo is that over-expressed ERb or activation
of ERb with selective agonists impaired COX7AR expression.
Mechanistically, this effect of ERb on COX7AR expression is
probably mediated by ERb binding to the perfect palindromic
estrogen-responsive element (ERE) identified in the first intron of
the COX7AR gene.44 That normal ERb-positive mesothelial cells did
not respond to treatment with ERb-selective agonists, can be
explained by their lower proliferative activity, different energetic
profile and/or the presence of co-regulators and other trans-
cription factors that act in concert with ERb to maintain normal
cellular functions.
The observed in vitro effects on tumor cells were recapitulated
in vivo in a MMe mouse model. In contrast to the aggressive tumor
growth in mice xenografted with the ERb-negative MSTO-211H
cells and the lack of effect by treatment with KB9520, animals
injected with the ERb-expressing REN cells showed decreased
tumor growth rate and tumor volume in response to KB9520.
These data further strengthen the role of ERb as a tumor
suppressor, and that the antitumor effect of KB9520 is target
specific. Moreover, we could confirm that the KB9520-induced
inhibitory effects on MRC complex II and IV, and the repressive
effects on COX7AR gene expression in vitro translates to the in vivo
mesothelioma tumor model treated with the ERb-selective agonist
KB9520. Interestingly, in tumor tissues recovered from REN-
injected mice, treatment with KB9520 resulted in increased ERb
expression at both the levels of transcription and protein,
compared with vehicle-treated controls. The mechanism for the
increased ESR2 gene activity is not clear and needs further
characterization.
As often observed in numerous forms of cancer, mitochondrial
dysfunction may contribute to the preference for glycolysis and
glutaminolysis to produce adequate amounts of ATP for cell
growth and/or survival.28,45,46
We observed that cells in which ERb was activated, did not
present a classical Warburg effect, although they were strongly
dependent on glycolysis to survive. These alterations in energy
production reflect also their reduced cell proliferation, and this
may represent yet another mechanism by which ERb acts as a
tumor suppressor. In fact, the glycolytic pathway produces only
two molecules of ATP per molecule of glucose, which is well below
the 36 molecules of ATP per molecule of glucose produced by
OXPHOS. Consistent with the inhibition of OXPHOS, KB9520 in
combination with the hexokinase inhibitor 2-Deoxy-D-glucose or
the PFKFB3 kinase inhibitor 3PO, two drugs that target important
rate-limiting enzymes in the glycolysis pathway resulted in
synergistic inhibition of MMe cell growth.
In summary, our data suggest that treatment with an ERb
agonist alone or in combination with glycolysis inhibitors may be
a future strategy for clinical management of ERb-positive MMe
and peritoneal mesothelioma.
MATERIALS AND METHODS
Reagents and antibodies
The monoclonal antibodies specific for a-tubulin, lamin and the polyclonal
antibody specific for ERb were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The monoclonal antibody for one subunit of
each MRC complex (MIX OXPHOS) was obtained from MitoSciences
(Eugene, OR, USA). Anti-mouse and anti-rabbit immunoglobulin G
peroxidase-conjugated antibodies, 2DG and chemical reagents were
obtained from Sigma-Aldrich (St Louis, MO, USA). ECL was obtained from
Amersham Pharmacia Biotech (Uppsala, Sweden). Nitrocellulose mem-
branes and protein assay kit were obtained from Bio-Rad (Hercules, CA,
USA). Culture media, sera, antibiotics and LipofectaMINE transfection
reagent were obtained from Invitrogen (Carlsbad, CA, USA). ERb-specific
agonist DPN was obtained from Tocris (Bristol, UK), and KB9520 and 3PO
were provided by Karo Bio AB (Huddinge, Sweden). (KB9520 has been
described previously.14,15 The compound can be obtained following
contact with Karo Bio AB and after signing of a Material Transfer
Agreement together with a detailed protocol of planned study. A fee
covering the cost of compound synthesis will be charged).
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Figure 6. ERb activation sensitizes cells to glycolysis inhibitors.
(a) The bar graph compares data of cell survival at different times in
a glucose-deprived medium of Mock, ERb over-expressing (ERb) or
ERb-silenced (shERb) REN cells. (b) The bar graph compares data of
cell count of ERb over-expressing, wild type in the presence of 10 nM
KB9520 (24 h) and ERb-silenced (72 h) REN cells, treated with 10mM
2-Deoxy-D-glucose. (c) The bar graph compares data of viability of
ERb over-expressing, wild type in the presence of 10 nM KB9520
(24 h) and ERb-silenced (72 h) REN cells, treated with 10 mM PFKFB3
kinase inhibitor 3PO. Each graph is representative of three
independent experiments. Each bar represents mean±s.d. *Po0.05.
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Cell cultures and transfection
The epithelioid MMe-derived REN cell line, used as the principal
experimental model in this investigation, was isolated, characterized47
and kindly provided by Dr Albelda SM (University of Pennsylvania,
Philadelphia, PA, USA). The biphasic-derived MSTO-211H and the
mesothelial MET5A cell lines were obtained from the Istituto Scientifico
Tumori (IST) Cell-bank, Genoa, Italy. Cells were cultured in standard
conditions. Cells were transiently transfected with the pCNX2 plasmid
expressing human wild-type ERb (Addgene, Cambridge, MA, USA) using
LipofectAMINE (Invitrogen) reagent as described by the manufacturer.
Gene silencing was achieved using an ERb-specific shRNA lentiviral
plasmid (pLKO.1-puro) (Sigma-Aldrich) or ESR2 and SDHB-specific siRNAs
by Qiagen (Hilden, Germany). The plasmid expressing human ERb mutated
in the DBD was kindly provided by Dr Stro¨m A (University of Houston,
Houston, TX, USA).48
Proliferation assay by cell count
Cells seeded at a density of 10 104 cells/well on six-well plates were
alternatively treated with the indicated molecules or transiently trans-
fected by the LipofectAMINE reagent, as described by the manufacturer.
Cells were then trypsinized and stained with Trypan blue. The number of
cells considered viable was counted in a Bu¨rker hemocytometer within
5min after staining.
Cell lysis and immunoblot
Cells were extracted with 1% NP-40 lysis buffer (1% NP-40, 150mM NaCl,
50mM Tris-HCl (pH 8), 5mM EDTA, 10mM NaF, 10mM Na4P2O7, 0.4mM
Na3VO4, 10mg/ml leupeptin, 4mg/ml pepstatin and 0.1 U/ml aprotinin). Cell
lysates were centrifuged at 13 000 g for 10min, and the supernatants were
collected and assayed for protein concentration with the Bio-Rad protein
assay method. Proteins were separated by SDS-PAGE under reducing
conditions, transferred to nitrocellulose, reacted with specific antibodies
and detected with peroxidase-conjugate secondary antibodies and
chemioluminescent ECL reagent. Densitometric analysis was performed
using the GS 250 Molecular Image (Bio-Rad).
Preparation of nuclear and cytoplasmic protein fractions
Phosphate-buffered saline-washed cell pellets were resuspended in 10
volumes of buffer 1 (15mM Tris pH 7.5, 0.8mM KCl, 0.25mM EDTA and
Sigma protease cocktail). Cells were then allowed to recover for 5min at
4 1C, and 10% NP-40 was added dropwise. The lysed cells were centrifuged
at 1000 g. The supernatant (cytoplasmic fraction) was decanted, and the
pellet (corresponding to the nuclei) was resuspended in extraction buffer
(20mM Tris-HCl (pH 8.5) 10% glycerol, 2mM DTT and 0.8 KCl). The DNA was
shared by passage through a 25-gauge syringe, and incubated for 45min
on ice. The mixture was centrifuged at 13 000 g, and the nuclear fraction
was resuspended in 150mM KCl in extraction buffer. Cellular fractions were
analyzed by immunoblotting.
RNA, DNA isolation and quantitative real-time PCR
Total RNA was extracted using the guanidinium thyocianate method.49
Starting from equal amounts of RNA, cDNA used as template for
amplification in the real-time PCR (5 mg), was synthesized by the reverse
transcription reaction using RevertAid Minus First Strand cDNA Synthesis
Kit from Fermentas–Thermo Scientific (Burlington, ON, Canada), using
random hexamers as primers, according to the manufacturer’s instructions.
As a PCR internal control, ACTB was simultaneously amplified using the
primers: Fw 50-CTTCCTTCCTGGGCA-30 and Rev 50-TGTGTTGGCGTACAG-30 .
The primers sequences for ESR2 were: Fw 50-GTCAGGCATGCGAGT-30
and Rev 50-GGGAGCCCTCTTTGC-30 ; SDHB and COX7AR primers were
CII
SDHB
CIV
COX7AR
ATP
Impaired
mitochondrial function
Glycolysis
dependence
Reduced cell propagation in vitro
and tumor growth in vivo
CI
CIII
ATP
synthase ER
Figure 7. Schematic representation of the proposed mechanism.
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QT00066507 and QT01012368 from Qiagen (Hilden, Germany). For a
quantitative analysis of mtDNA content, total genomic DNA was extracted
from previously transfected cells using the NucleoSpin kit (Macherey-
Nagel, Du¨ren, Germany); primers for D-loop, mtDNA sequence and ACTB
nuclear DNA sequences, obtained from Eurofins MWG Operon (Ebersberg,
Germany), were used as described.50 The real-time reverse transcription–
PCR (RT–PCR) was performed using the double-stranded DNA-binding dye
SYBR Green PCR Master Mix (Fermentas–Thermo Scientific) on an ABI
GeneAmp 7000 Sequence Detection System machine, as described by the
manufacturer. Graphical Cycle threshold (Ct) values were obtained
automatically by the instrument, for each gene tested. Triplicate reactions
were performed for each marker and the melting curves were constructed
using Dissociation Curves Software (Applied Biosystems, Foster City, CA,
USA), to ensure that only a single product was amplified.
Measurement of respiratory chain complexes activities
Measurements of respiratory chain complexes activities were carried out in
mitochondrial membrane-enriched fractions from cultured cells or tumor
samples. Aliquots of trypsinized cells were washed with ice-cold
phosphate-buffered saline, frozen in liquid nitrogen and kept at  80 1C
until use. Tumor samples were homogenized in a medium containing
0.25 M sucrose, 2mM EDTA and 20mM Tris-HCl, pH 7.5 (20ml/mg tissue) and
centrifuged at 5500 g, 3min at 4 1C. The supernatant was centrifuged twice
at 8500 g, 10min at 2–4 1C. Pellet were frozen in liquid nitrogen and kept at
 80 1C until use. Isolation of mitochondrial membrane-enriched fractions
and measurement of respiratory chain complexes activities were
performed essentially as described in ref. 51.
Measurement of mitochondrial ATP production
Cells previously transfected were trypsinized, washed with PBS and
suspended in ice-cold sucrose medium (0.25 M sucrose, 10mM Tris/HCl pH
7.2, 1mM EGTA and 0.01% (w/v) digitonin), to permeabilize cell membranes
as previously described.52 To measure the mitochondrial ATP production,
permeabilized cells (1mg of protein) were incubated at 37 1C in 1.5ml of
the respiration medium (210mM mannitol, 70mM sucrose, 20mM TRIS-HCl,
5mM KH2PO4/K2HPO4 (pH 7.4), 3mM MgCl2 and 5mg/ml BSA), with either
GLU (glutamate, 5mM) plus MAL (malate, 5mM) (complex I substrates) or
SUCC (succinate, 5mM) (complex II substrate). During the analysis, Ap5A
(adenylate kinase inhibitor) was added to be sure to measure only the
OXPHOS produced ATP.
Preparation of samples for electron microscopy
Cells transiently transfected with the pCNX2 ERb plasmid, empty vector,
SDHB siRNAs or non-silencing siRNA were trypsinized, washed with PBS
and then fixed in a cacodylate buffer (2.5% glutaraldehyde, 0.1 M
cacodylate; pH 7.2) for 2 h at 4 1C. After two washings in cacodylate
buffer, 0.1 M samples were processed as described in ref. 53. Ultrathin
sections were placed on Formvar carbon-coated copper grids, stained with
uranyl acetate and lead citrate, and observed under a Jeol 100 SX
transmission electron microscope (Jeol, Ltd, Tokyo, Japan).
Determination of mitochondrial mass
Mitochondrial mass was determined by using the fluorescent dye NAO (10-
n-nonyl-Acridine Orange; Molecular Probes, Eugene, OR, USA).54 Sub-
confluent cells were trypsinized and resuspended in 0.5ml of culture
medium (5 105 cell/ml) supplemented with 25mM Hepes, pH 7.5, and
containing 5 mM NAO. After incubation for 10min at 37 1C, cells were spun
down, washed with ice-cold medium and transferred immediately into a
tube on ice for analysis of the fluorescence intensity by flow cytometry. In
each measurement, a minimum of 20 000 cells was analyzed. Data were
acquired and analyzed on the FL2 channel using CellQuest software
(Becton Dickinson, San Jose, CA, USA).
Survival assay in glucose-deprived medium
REN cells seeded at a density of 10 104 cells/well on six-well plates and
incubated overnight were transiently transfected with the pCNX2 ERb
plasmid, ERb shRNA and empty vector or siRNA by the LipofectAMINE
reagent, as described by the manufacturer. Twenty-four hours later, the
transfected cells were grown in a glucose-deprived medium containing
galactose. Cells were then trypsinized and stained with Trypan blue. The
number of cells considered viable was counted in a Bu¨rker hemocytometer
within 5min after staining.
In vivo experiments
Animals. CD1 nude mice (males, 6 weeks old; Charles River, Calco, Italy)
received i.p. injections of 2 106 REN or 1 106 MSTO-211H luciferase-
transduced MMe cells. After anesthetization and i.p. injections of 0.3ml of
15mg/ml D-luciferin, tumor dimension and localization of luminescent
cells was monitored using the In Vivo Imaging System (IVIS) system 100
series (Xenogen Corporation, Hopkinton, MA, USA). Regions of interest
were quantified as total photon counts using Living Image software
(Xenogen Corporation). To evaluate treatment toxicity, mice were weighed
at the start and end of treatments. Mice were killed and necropsied after
20 days of treatment. In vivo experiments were approved by Istituto
Scientifico Tumori (Genoa, Italy) ethical committee and conform to the
relevant regulatory standards.
Drug administration. An elapse of 15 days was allowed for the formation
of detectable tumor nodules by IVIS imaging. Mice were then weighed and
stratified into each treatment group of seven animals. Treatment protocols
were done from the 15th day to the 35th day, and mice were analyzed
weekly by IVIS imaging to assess tumor growth. One dose of KB9520 was
used (10mg/kg body weight/day). KB9520 dissolved in the vehicle (5%
DMSO/40% PEG 400/55% water) was administrated once daily by
subcutaneous administration. Untreated animals were subcutaneously
dosed with empty vehicle. At day 35, mice from the two groups were
euthanized and necropsied. Tumors growing in the peritoneum were
excised, and one part of the tumor tissue was immediately frozen.
Statistical analysis
Statistical evaluation of the differential analysis was performed by one-way
analysis of variance and Student’s t-test. The threshold for statistical
significance was set at Po0.05.
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